FOR U.S. HEALTHCARE PROFESSIONALS
ABBVIE MEDICAL AFFAIRS
The hepatitis C virus (HCV) landscape has changed
who is affected
types of providers
New cases of acute HCV have increased 375% since 20101
~44,300 estimated new cases of acute hepatitis C in 20171
CDC = Centers for Disease Control and Prevention
New infections increasing the most among 20- to 29-year-olds1
~8 out of 10 new HCV infections in 2014 in people who inject drugs (PWID)2
~2.3 million adults in the United States infected with HCV3
~40% unaware of infection4
There is good news
Today, interferon-free, all-oral DAA regimens offer short treatment durations and ...5
DAA = direct-acting antiviral
can cure* more than 95% of persons with HCV5,6
*Cure means the hep C virus is not detectable in the blood 3 months after treatment ends.7
2 out of 3 physicians believed patients did not have adequate access to providers in their community8
—According to a 2013 survey
Do we have enough providers needed to treat future patients?
Today’s regimens have been used effectively in nonspecialist settings, including in primary care.9,10
Expanding the treatment of HCV to nonspecialty settings helps reach and treat underserved populations:10,11
This expanded group of providers can include remote specialist oversight
allowing for more patients treated
and reduce specialist resource utilization12
The paradigm for treating HCV is shifting further—to non-MD clinical providers:13
The landscape has changed and comprehensive resources are needed sooner rather than later.
That’s why we developed HCV.com, with resources designed to help
Offering: Disease education
Offering: Treater resources
Offering: Discussion tools
The World Health Organization 2030 goal for HCV elimination is just 10 years away.14
At AbbVie, we believe that goal is achievable.
That’s why you’re here.
Welcome to HCV.com
1. Centers for Disease Control and Prevention. Surveillance for viral hepatitis – United States, 2017. https://www.cdc.gov/hepatitis/statistics/2017surveillance/index.htm. Updated November 19, 2019. Accessed October 16, 2020.
2. Zibbell JE, Asher AK, Patel RC, Kupronis B, Iqbal K, Ward JW, et al. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health. 2018;108(2):175-181. doi:10.2105/AJPH.2017.304132
3. Rosenberg ES, Rosenthal EM, Hall EW, Barker L, Hofmeister MG, Sullivan PS, et al. Prevalence of hepatitis C virus infection in US states and the District of Columbia, 2013 to 2016. JAMA Netw Open. 2018;1(8):e186371. doi:10.1001/jamanetworkopen.2018.6371
4. Yehia BR, Schranz AJ, Umscheid CA, Lo Re V III. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One. 2014;9(7):e101554. doi:10.1371/journal.pone.0101554
5. Lam BP, Jeffers T, Younoszai Z, Fazel Y, Younossi ZM. The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Therap Adv Gastroenterol. 2015;8(5):298-312. doi:10.1177/1756283X15587481
6. World Health Organization. Hepatitis C. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c. Updated July 27, 2020. Accessed October 16, 2020.
7. American Association for the Study of Liver Diseases/Infectious Diseases Society of America. When and in whom to initiate HCV therapy. https://www.hcvguidelines.org/evaluate/when-whom. Updated November 6, 2019. Accessed October 16, 2020.
8. McGowan CE, Monis A, Bacon BR, Mallolas J, Goncales FL, Goulis I, et al. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology. 2013;57(4):1325-1332. doi:10.1002/hep.26246
9. Georgie F, Nafisi S, Kohli A, et al. Primary care physicians utilizing the ECHO model equally effective as subspecialists treating HCV using direct-acting antivirals-only regimens: results of the ECHO model [Abstract SAT-260]. J Hepatol. 2016;64(suppl 2):S818-S819.
10. Kattakuzhy S, Gross C, Emmanuel B, Teferi G, Jenkins V, Silk R, et al; ASCEND Providers. Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial. Ann Intern Med. 2017;167(5):311-318. doi:10.7326/M17-0118
11. Beste LA, Glorioso TJ, Ho PM, Au DH, Kirsh SR, Todd-Stenberg J, et al. Telemedicine specialty support promotes hepatitis C treatment by primary care providers in the Department of Veterans Affairs. Am J Med. 2017;130(4):432-438.e3. doi:10.1016/j.amjmed.2016.11.019
12. Thomas J, Thompson H, Wu T, Khokhar A, Kentwell S, Rahman TM. Direct‐acting antiviral therapy in primary care following non‐real time, remote specialist review – a practical solution to scaling up HCV therapy [Abstract 474]. Hepatology. 2018;68(suppl 1):465A-466A.
13. Butt AA, Yan P, Lo Re Iii V, Shaikh OS, Ross DB. Trends in treatment uptake and provider specialty for hepatitis C virus (HCV) infection in the Veterans Affairs healthcare system: results from the electronically retrieved cohort of HCV-infected veterans (ERCHIVES). Clin Infect Dis. 2019;68(5):857-859. doi:10.1093/cid/ciy697
14. World Health Organization. Combating hepatitis B and C to reach elimination by 2030. May 2016. https://www.who.int/hepatitis/publications/hep-elimination-by-2030-brief/en/. Accessed October 16, 2020.